The Office of Cancer Genomics (OCG)Opens in a New Tab, along with the Office of HIV and AIDS Malignancies (OHAM)Opens in a New Tab, initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients. The molecular characterization data from patients identified through HTMCP will be available to the research community worldwide in a publicly available, yet patient privacy-protected database.
Acquired immunodeficiency syndrome (AIDS)Opens in a New Tab is a complex and devastating disease caused by infection with human immunodeficiency virus (HIV)Opens in a New Tab. The advent of highly active anti-retroviral therapy (HAART) has considerably slowed disease progression from HIV to full-blown AIDS, thereby increasing the number of people living with HIV. Despite this success in survivorship, certain types of cancers are becoming more prevalent in the expanding pool of HIV-infected individuals. This poses a challenge to global health, since at the end of 2014 approximately 36.9 million people were living with HIV worldwide (25.8 million in Sub-Saharan Africa and over 1 million in the US, according to the World Health Organization). While co-infecting viruses and, possibly, immunodeficiency may play a role in the pathogenesis of HIV-associated cancers, our understanding of its etiology is inadequate. Understanding the molecular causes of these tumors may translate into improved therapies for a growing population of patients doubly afflicted with HIV and cancer.
HTMCP is an ongoing project that is currently in Phases 1 and 2 of the timeline.
Visit the CGCI Overview page to learn more about the general timeline of CGCI projects.